Scalper1 News
Two biotechs treating eye diseases were making huge moves in opposite directions Tuesday morning after equally different drug news came out late Monday. Aerie Pharmaceuticals (AERI) stock soared more than 50%, near 20, and the company got an upgrade after it said that the FDA had agreed to a redesign of a clinical trial of beleaguered glaucoma treatment Rhopressa. Aerie’s stock tumbled 64% on April 24, near 13, after a phase-three trial, called Scalper1 News
Scalper1 News